Publication | Closed Access

Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice

InflammationThrombosisVascular DiseaseApoe-deficient MiceCardiovascular DiseaseMedicineImmunologyCardiovascular PharmacologyVascular BiologyPharmacotherapyAtherosclerotic Plaque ProgressionPharmacologyAnticoagulantAtherosclerosisNovel Oral AnticoagulantOxidative Stress